Do neutrophil- lymphocyte, platelet-lymphocyte ratio correlate with pathological outcomes in localized renal tumors?
preprint
OA: closed
CC-BY-4.0
Abstract
Abstract Background: We investigated the association of the blood parameters such as neutrophil, platelet accounts and neutrophil/lymphocyte ratio (NLR) with tumor type, tumor size and Fuhrman grade in nonmetastatic renal cell carcinoma (RCC) cases. Methods: A total of 343 patients with nonmetastatic (T1- 4N0M0) RCC were included into the study. The patients were divided into four groups: clear cell (group-1), papillary (group-2), chromophobes (group-3) and other pathologies (group-4). In each grouping systems, the NLR, white blood cell (WBC), platelet (PLT), mean corpuscular hemoglobin (MCH), and mean corpuscular volume (MCV) values were compared. Results: There were 222 patients with clear cell (group-1), 62 papillary (group-2), 16 chromophobes (group-3) and 43 patients with other pathologies (group-4). There was a significant difference between the groups in group-1 and group-3 in terms of white blood cell (WBC), platelet (PLT), lymphocyte and neutrophil count. However, there was no significant difference between the groups by the surveys in terms of Neutrophil / Lymphocyte Ratio (NLR) values. There was no significantly difference between survival and NLR either. Conclusion: NLR is a cheap and easy parameter to calculate but is not suitable to predict tumor prognosis and survival yet. NLR cut-off value is the biggest problem for now. But evidences show, we are too close to overcome this problem.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00
- unpaywall
- last seen: 2026-05-29T02:00:03.542394+00:00
License: CC-BY-4.0